Chronic intermittent hypoxia-induced deficits in synaptic plasticity and neurocognitive functions: a role for brain-derived neurotrophic factor

Hui XIE, Wing-ho YUNG*

School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China

Obstructive sleep apnea (OSA) is well known for its metabolic as well as neurobehavioral consequences. Chronic intermittent hypoxia (IH) is a major component of OSA. In recent years, substantial advances have been made in elucidating the cellular and molecular mechanisms underlying the effect of chronic IH on neurocognitive functions, many of which are based on studies in animal models. A number of hypotheses have been put forward to explain chronic IH-induced neurological dysfunctions. Among these, the roles of oxidative stress and apoptosis-related neural injury are widely accepted. Here, focusing on results derived from animal studies, we highlight a possible role of reduced expression of brain-derived neurotrophic factor (BDNF) in causing impairment in long-term synaptic plasticity and neurocognitive functions during chronic IH. The possible relationship between BDNF and previous findings on this subject will be elucidated.

Keywords: obstructive sleep apnea; intermittent hypoxia; synaptic plasticity; long-term potentiation; brain-derived neurotrophic factor

Introduction
Obstructive sleep apnea (OSA), a very common breathing and sleep disorder, is associated with intermittent hypoxia (IH) resulting from upper airway obstruction of structural or neural causes[1, 2]. The most distinct features of OSA are episodes of oxyhemoglobin desaturations, which are terminated by brief periods of microarousals that could lead to sleep deprivation, fragmentation and alteration in sleep pattern[3]. During OSA, arterial O2 saturation could drop to very low level (50%–60%) within every cycle. This problem is alarmingly common and likely to be over-looked by the general population. The prevalence in men and women have been estimated to be 24% and 9% respectively if we only assess the frequency of increased obstructive events during sleep[4]. A large variety of problems are associated with OSA, including cardiovascular morbidity, hypertension, obesity, dyslipidemia, insulin resistance, and neurocognitive malfunctions[5, 6]. Because of the prevalence of OSA, there is a substantial cost that the society has to pay for their treatment, and also the failure in their diagnosis. In addition, OSA incurs society costs in the form of reduced work efficiency, occupational and motor vehicle accidents, decreased quality of life and morbidity. Statistical analysis confirmed that treatment reduces the medical cost of OSA[7], highlighting the significance and impact of improving available treatment strategies.

OSA and neurological functions
It is well known that OSA is not just a breathing disorder with metabolic consequences. The cyclic hypoxia and sleep fragmentation could lead to impaired brain functions which severely degrade performance in daily lives and work, and is one of the major causes of sleepiness and concentration-deficit related traffic accidents. It is well known that OSA results in cognitive deficits including decreased attention and vigilance, phonological problem, irritability, impairment in executive functions and long-term memory[8–13]. However, very little is known about the detailed events happening in the central nervous system in OSA subjects, and the relative roles of sleep fragmentation and intermittent hypoxia. Furthermore, although surgery and continuous positive airway pressure (CPAP) are useful treatments for OSA, whether long-term changes happening in the brain could be reverted is not known. These are important questions to be addressed and the answers are just beginning to be unraveled.
Chronic IH-induced impairment in memory and neuroplasticity

There are a large number of studies in human OSA subjects to investigate the origin of the neurocognitive problems, many of which are based on brain imaging. Techniques such as structural magnetic resonance imaging and proton magnetic resonance spectroscopy revealed significant changes in various brain regions and metabolism in OSA patients[15]. It should be pointed out that, because of the simultaneous occurrence of intermittent hypoxemia and sleep fragmentation in OSA, dissecting the influences of these two factors on cognitive functions, and what aspects of cognition, are difficult in human subjects. Understandably, these techniques are limited in providing mechanistic explanation of the pathological events at the cellular level. On the other hand, based on animal models, attempts and significant advances have been made in the last decade in unveiling the relationship between OSA and cognitive dysfunction and the underlying mechanisms.

To assess the neurobehavioral effects of episodic hypoxia in the absence of sleep fragmentation, Gozal and colleagues in early years established an animal model to study the anatomical and behavioral correlates of chronic episodic hypoxia in the rat[11, 13]. They established that exposure to IH during sleep cycle of adult rats is associated with significant spatial learning deficits as well as increased neuronal loss within susceptible brain regions such as the hippocampus and cortex. Subsequent studies have confirmed that chronic IH treatment, as well as sleep fragmentation, as models of OSA, could impair spatial memory functions of rodents to different degrees, as measured by the conventional water maze tests[16–22].

There are a number of factors and pathways that have been proposed to account for the effects of OSA-associated IH and sleep disturbance on neurocognitive functions. An early notion asserted that episodes of hypoxia could trigger apoptosis programs in neurons in areas including the hippocampus and cortex, and could lead to cytoarchitectural disorganization[11, 16]. In fact, apoptosis in the hippocampal CA1 region could be detected as early as 1–2 d in the IH-treated rats, preceding the appearance of memory deficits[11]. Consistent with this idea, a significant number of hippocampal slices obtained from the hypoxic animals failed to exhibit tetanus-induced potentiation of populations spikes, measured at 15 min post-stimulation[23]. The effects on the conventional early phase (te up to 1 h) and late-phase (longer than 3 h) long-term potentiation (LTP) were however not addressed in this study.

The relatively mild degree of apoptosis detected in the brains of the IH animals[11] raises the question of whether apoptosis could explain the neurocognitive malfunctions of the animals. In fact, it is possible that chronic IH can cause a general compromise of oxidative phosphorylation and consequently poor maintenance of ion gradients of neurons. In other words, the physiological function of the neurons may be compromised before explicit apoptosis. There were few attempts to examine the direct effects of chronic IH on the excitability of hippocampal neurons, and their synaptic transmission, in the animal model of OSA. Nevertheless, it has been shown that in the developing nervous system, IH will affect neuronal excitability and its maturation by altering the expression of Na channels and ion transporters[24, 28]. In the adult mice, we also found that chronic IH decreases membrane input resistance and excitability of hippocampal CA1 neurons[26].

The reasons for the compromised neuronal function or apoptosis in the hippocampus or other brain areas are not entirely known. However, it is highly probable that oxidative stress plays a significant role (reviewed by WANG et al[27]). Thus, it has been well established that there are increased expressions of oxidative stress markers found in the brains of rodents subjected to IH treatment[28–30]. Administration of antioxidants[29] or over-expressing superoxide dismutase[30] attenuated reactive oxygen species (ROS) production and apoptosis in chronic IH-treated animals. More recent evidence supports a specific role of NADPH oxidase in IH-induced oxidative stress[31, 32]. However, up to now, the source and mechanism of ROS generation and its impact on neurocognitive deficits in IH are not entirely clear.

There exist other possible mechanisms by which IH could affect the hippocampus and therefore learning and memory behaviours. For example, FUNG et al[33] suggested that intermittent hypoxia produces abnormally high level of glutamate and causes excitotoxicity in hippocampal neurons. LI et al[34] concluded from their study that intermittent hypoxia in the rat is associated with an increased expression of iNOS which may play a critical role in IH-mediated neurobehavioural deficits. Furthermore, inflammation, which has been shown to play important roles in mediating the peripheral effects of IH[35], may contribute to neural injury in the brain[36].

It is well known that the hippocampal circuit is critical for the formation of spatial memory. However, a causal relationship between chronic IH and hippocampal synaptic plasticity has not been established until very recently. In a recent study based on a mouse model of OSA, we showed for the first time that there was a significant decrease in early phase long-term potentiation (E-LTP) in the hippocampi of both 7-d and 14-d IH-treated mice, while there was no apparent effect on the 3-d IH group[26]. This result provides an explanation for the well-documented memory deficits associated with OSA and its models. Of importance, it was demonstrated that not only the conventional E-LTP was impaired by IH, but the late-phase LTP (L-LTP), which better correlates with the formation of long-term memory, was also impaired and to a more significant extent. However, whether those factors that have been proposed to contribute to cognitive dysfunction, namely oxidative stress, apoptosis, decreased neuronal excitability, excitotoxicity, inflammatory response etc, is a cause of impaired LTP has not been demonstrated.

Critical role of decreased BDNF expression in chronic intermittent hypoxia

Brain-derived neurotrophic factor (BDNF), as a member of the neurotrophin family, plays key roles in neuronal survival and differentiation during development[37–39]. BDNF is also known...
to be expressed and released in an activity-dependent manner in the central nervous system and can acutely modulate synaptic transmission and plasticity\(^{40-43}\). In a previous study, we and co-workers reported that BDNF is critical in the expression of L-LTP in the hippocampus suggesting that it is a key protein in long-term memory formation\(^{44}\). Consistent with this idea, a single amino acid polymorphism in the BDNF gene has been shown to affect the cortical morphology and memory in human\(^{45, 46}\). In addition, the conversion of proBDNF to mature form of BDNF is tightly regulated by central tissue plasminogen activator (tPA) which catalyses the conversion of plasminogen to plasmin. Plasmin then cleaves proBDNF to mature BDNF.

In our study on the chronic IH mouse model\(^{26}\), we found that the expression of BDNF was reduced significantly after chronic IH treatment. Compelling evidence for critical role of BDNF was provided by showing that exogenous application or surgical replenishment of BDNF by intraventricular injection could rescue and prevent, respectively, IH-induced LTP deficits. Thus, BDNF could be a crucial factor contributing to the absence of normal hippocampal plasticity and therefore memory function in the IH model.

At present, the exact reason causing BDNF decrease in chronic IH is unknown. Being a neurotrophic factor, the level of BDNF has been shown to be increased under some pathological conditions of the brain\(^{47, 48}\) and spinal cord\(^{49}\). This is usually regarded as a compensatory mechanism by the nervous system to help boost the survival of neurons. However, prolonged insult such as chronic IH may compromise the ability of neurons, and probably astrocytes as well, to express BDNF. The time-dependent decrease in BDNF level we found in our chronic IH model is in line with this notion. Interestingly, the level of another neurotrophic factor, NT4/5, was not decreased (unpublished data) indicating that the effect of IH on BDNF is specific, and also argues against the possibility that the decrease in BDNF level is simply due to neuronal loss. It is known that chronic IH affects gene transcription, including those driven by CREB\(^{16}\). While the total CREB production remains unchanged, the phosphorylated form of CREB was reduced, maximally at 3 d, after hypoxic treatment. Since BDNF is a CREB-dependent gene product, the impact of chronic IH at the gene level could provide an explanation of the observed decrease in BDNF expression. On the other hand, we found that the expression of plasmin, the extracellular enzyme that helps to cleave pro-BDNF to mature forms of BDNF is reduced in the chronic IH model (unpublished data). This result is consistent with our observation that the proBDNF level is not significantly affected by chronic IH treatment, and points to a role of proteolytic cleavage of proBDNF to mature BDNF rather than transcription of BDNF gene.

It should be pointed out that, in our study, although we did not specifically induce sleep fragmentation or deprivation on the subjects, the loss or interference in sleep could contribute to a certain extent the observed changes in BDNF as the sleep architecture may be affected\(^{50, 51}\). Furthermore, a recent study employing a chronic IH paradigm with a much longer cycle length resulted in an enhancement of BDNF expression in the hippocampus\(^{52}\), and in another study, a less severe paradigm of daily intermittent hypoxia also augments BDNF expression in the spinal cord\(^{53}\). These results suggest that the number and frequency of hypoxia/re-oxygenation cycles could be a major factor in determining the effect on BDNF expression.

**Relationship between BDNF, oxidative stress, and apoptosis**

As described above, oxidative stress induced by repeated hypoxia/re-oxygenation challenge and ROS-induced apoptosis are two closely-related factors that are widely accepted to contribute to neuronal damage under chronic IH condition\(^{27}\). Given our discovery of the importance of BDNF in restoring hippocampal functions in IH animals, how can we reconcile our findings with these hypotheses? There is growing evidence that neurotrophic factors such as BDNF can significantly prevent neuronal damage caused by oxidative stress, as in neurodegenerative diseases (reviewed by NUMAKAWA et al\(^{54}\)), or as shown in *in vitro* cultures against ROS generation and action directly\(^{55}\). Thus, it is possible that lack of BDNF in chronic IH not only contributes to impaired long-term synaptic plasticity but also fails to prevent neuronal injury, including apoptosis, induced by ROS. In other words, lack of BDNF is a key factor in the cascades of events leading to neurocognitive deficits in OSA, as depicted in Figure 1. In this model, chronic IH could lead directly to decrease in neuronal excitability, and also results in an enhancement of BDNF expression. BDNF is a CREB-dependent gene product. Therefore, it is possible that lack of BDNF in chronic IH not only contributes to impaired long-term synaptic plasticity but also fails to prevent neuronal injury, including apoptosis, induced by ROS. In other words, lack of BDNF is a key factor in the cascades of events leading to neurocognitive deficits in OSA, as depicted in Figure 1. In this model, chronic IH could lead directly to decrease in neuronal excitability, and also results in an enhancement of BDNF expression. BDNF is a CREB-dependent gene product. Therefore, it is possible that lack of BDNF in chronic IH not only contributes to impaired long-term synaptic plasticity but also fails to prevent neuronal injury, including apoptosis, induced by ROS. In other words, lack of BDNF is a key factor in the cascades of events leading to neurocognitive deficits in OSA, as depicted in Figure 1. In this model, chronic IH could lead directly to decrease in neuronal excitability, and also results in an enhancement of BDNF expression.

**Figure 1.** Proposed interactions between BDNF reduction and other pathological processes that lead to neuronal injury and decreased neuroplasticity in OSA. Chronic intermittent hypoxia and/or sleep fragmentation leads directly to decrease in neuronal excitability, decrease in BDNF expression and generation of ROS. These factors act together in a synergistic manner to increase apoptosis and also impairment in long-term synaptic plasticity underlying memory function. In this model, decreased expression of BDNF plays a pivotal role in ROS generation, apoptosis as well as impairment in synaptic plasticity.
ability, BDNF level and the generation of ROS. These factors act together in a synergistic manner to increase apoptosis and also impairment in long-term synaptic plasticity underlying memory function. Obviously, further experiments are needed to scrutinize this hypothesis.

**Future directions**

Here we would like to highlight a few issues that interest us and at the same time that we feel are important. First, the establishment of the chronic IH model in mimicking the hypoxia/re-oxygenation cycles in OSA has advanced our understanding of the pathophysiology of OSA. However, the differential effects of IH on short-term working memory and long-term memory are far from clear. In fact, it has been suggested that sleep fragmentation has a selective effect on working memory function\([59]\). Thus, the impact of chronic IH vs sleep disturbance on different types of memory, as well as the involvement of BDNF level in these processes, are key issues that need to be addressed.

IH definitely affects neuronal functions, but despite the obvious importance, the question of exactly what happens to neuronal activities in different brain regions during IH has never been addressed. Previous attempts only relied on *in vitro* brain slice preparations and recordings could be made only after the animals had been sacrificed\([26, 57]\). Long-term recording of the firing properties of neurons *in vivo* during or after the IH will give a direct answer to this question and will provide big insight into the cause of cognitive dysfunctions in OSA.

One of the main thrusts in investigating the mechanisms of synaptic plasticity impairment and neurocognitive deficits in OSA models is to provide a scientific basis for potential pharmacological treatment. We have shown that multiple intraventricular injections of BDNF is beneficial to IH-induced LTP impairment in the mice model\([26]\). Therefore, the level of BDNF may be a novel therapeutic target to improve OSA-associated neurocognitive impairments. There were reports indicating that endogenous BDNF level could be elevated by short-term administration of specific compounds, for example, the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid AMPA receptor modulator ampakine\([59]\). Ampakines are a group of small molecules that can delay deactivation and reduce desensitization of AMPA type glutamate receptors and thereby increase the size and duration of ligand-gated current flow, enhancing glutamate transmission\([59, 60]\). In addition, previous studies showed that regular ampakine administration would increase the expression of BDNF. Considering that ampakines can also cross the blood-brain barrier, are bioactive orally and improve cognitive function without obvious side effects, they are of great potential and in fact have been partially proved to be candidate for a range of neurological disability and disturbances, including Alzheimer's disease and Huntington's disease\([58, 61–63]\). We hypothesize that ampakines are beneficial to the neurocognitive problems found in OSA by its action in elevating endogenous BDNF level in the brain. If proven, adjunct pharmacological treatment for cognitive problems in OSA would become feasible.

**Acknowledgements**

The authors’ work described in this article was supported by the Research Grants Council of Hong Kong, China (Project No 478308).

**References**

1. Caples SM, Gami AS, Somers VK. Obstructive sleep apnea. Ann Intern med 2005; 142: 187–97.

2. Mathieu A, Mazza S, De’cary A, Massicotte-Marquez J, Petit D, Gosselin N, et al. Effects of obstructive sleep apnea on cognitive function: A comparison between younger and older OSAS patient. Sleep Med 2007; 9: 112–20.

3. Deegan PC, McNicholas WT. Pathophysiology of obstructive sleep apnea. Eur Respir J 1995; 8: 1161–78.

4. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Eng J Med 1993; 328: 1230–5.

5. Lavie L. Oxidative stress — a unifying paradigm in obstructive sleep apnea and comorbidities. Prog Cardiovas Dis 2009; 4: 303–12.

6. Levy P, Bonsignore MR, Eckel J. Sleep, sleep-disordered breathing and metabolic consequences. Eur Respir J 2009; 34: 243–60.

7. Hoffman B, Wingenbach D, Kagey AN, Schaneman JL, Kasper D. The long-term health plan and disability cost benefit of obstructive sleep apnea treatment in a commercial motor vehicle driver population. J Occup Environ Med 2010; 52: 473–7.

8. Ali NJ, Pitson D, Stradling JR. Sleep disordered breathing: effects of adenotonsillectomy on behaviour and psychological functioning. Eur J Pediatr 1996; 155: 66–72.

9. Chervin RD, Dillon JE, Bassetti C, Ganoczy DA, PItuch KJ. Symptoms of sleep disorders, inattention, and hyperactivity in children. Sleep 1997; 20: 1185–92.

10. Gozal D. Sleep-disordered breathing and school performance in children. Pediatrics 1998; 102: 616–20.

11. Gozal D, Daniel JM, Dohanich GP. Behavioral and anatomical correlates of chronic episodic hypoxia during sleep in the rat. J Neurosci 2001; 21: 2442–50.

12. Gozal D. Effects of intermittent hypoxia on neurological function. In Brain Hypoxia and Ischemia 2009; (Eds Haddad GG, Yu SP). Humana Press.

13. Row BW, Kheirandish L, Neville JJ, Gozal D. Impaired spatial learning and hyperactivity in developing rats exposed to intermittent hypoxia. Pediatr Res 2002; 52: 449–53.

14. Tsai JC. Neurological and neurobehavioral sequelae of obstructive sleep apnea. NeuroRehabilitation 2010; 26: 85–94.

15. Jackson ML, Howard ME, Barnes M. Cognition and daytime functioning in sleep-related breathing disorders. Prog Brain Res 2011; 190: 53–68.

16. Goldbart A, Row BW, Kheirandish L, Schurr A, Gozal E, Guo SZ, et al. Intermittent hypoxic exposure during light phase induces changes in cAMP response element binding protein activity in the rat CA1 hippocampal region: Water maze performance correlates. Neuroscience 2003; 122: 583–90.

17. Goldbart A, Cheng ZJ, Brittan KR, Gozal D. Intermittent hypoxia induces time-dependent changes in the protein kinase B signaling pathway in the hippocampal CA1 region of the rat. Neurobiol Dis 2003; 14: 440–6.

18. Gozal D, Row BW, Gozal E, Kheirandish K, Neville JJ, Brittan KR, et al. Temporal aspects of spatial task performance during intermittent hypoxia.
hypoxia in the rat: evidence for neurogenesis. Eur J Neurosci 2003; 18: 2335–42.

19 Kheirandish K, Gozal D, Pequignot JM, Pequignot J, Row BW. Inter-

mittent hypoxia during development induces long-term alteration in

spatial working memory, monoamines, and dendritic branching in rat

frontal cortex. Pediatr Res 2005; 58: 594–9.

20 Kheirandish K, Row BW, Li RC, Brittan KR, Gozal D. Apolipoprotein

E-deficient mice exhibit increased vulnerability to intermittent hypoxia-

induced spatial learning deficits. Sleep 2005; 28: 1412–7.

21 Tartar JL, Ward CP, McKenna JT, Thakkar M, Arrigoni E, McCarley

RW, et al. Hippocampal synaptic plasticity and spatial learning are

impaired in a rat model of sleep fragmentation. Eur J Neurosci 2006;

23: 2739–48.

22 Ward CP, McCoy JG, McKenna JT, Connolly NP, McCarley RW, Strec-

ker RE. Spatial learning and memory deficits following exposure to

24 h of sleep fragmentation or intermittent hypoxia in a rat model of

obstructive sleep apnea. Brain Res 2009; 1294: 128–37.

23 Payne RS, Goldbart A, Gozal D, Schurr A. Effect of intermittent

hypoxia on long-term potentiation in rat hippocampal slices. Brain

Res 2004; 1029: 195–9.

24 Gu XQ, Haddad GG. Maturation of neuronal excitability in hippocam-

pal neurons of mice chronically exposed to cyclic hypoxia. Am J Physiol

Cell Physiol 2003; 284: C1156–63.

25 Zhao P, Xu J, Gu XQ, Haddad GG, Xia Y. Intermittent hypoxia

modulates Na+ Channel expression in developing mouse brain. Int J

Dev Neurosci 2005; 23: 327–33.

26 Xie H, Leung KL, Chen L, Chan YS, Cheung PK, Fok TF, et al. Brain-

derived neurotrophic factor rescues and prevents chronic intermittent

hypoxia-induced impairment of hippocampal long-term synaptic

plasticity. Neurobiol Dis 2010; 40: 155–62.

27 Wang Y, Zhang SXL, Gozal D. Reactive oxygen species and the brain

in sleep apnea. Respir Physiol Neurobiol 2010; 174: 307–16.

28 Row BW, Liu R, Xu W, Kheirandish L, Gozal D. Intermittent hypoxia

is associated with oxidative stress and spatial learning deficits in the rat.

Am J Respir Crit Care Med 2003; 167: 1548–53.

29 Zhan G, Fenik P, Pratico D, Vasey SC. Inducible nitric oxide synthase

in long-term intermittent hypoxia: hypersonnolence and brain injury.

Am J Respir Crit Care Med 2005; 171: 1414–20.

30 Xu W, Chi L, Row BW, Xu R, Ke Y, Xu B, et al. Increased oxidative

stress is associated with chronic intermittent hypoxia-mediated brain
cortical neuronal cell apoptosis in a mouse model of sleep apnea.

Neuroscience 2004; 126: 313–23.

31 Hui-guo L, Kui L, Yan-ning Z, Yong-jian X. Apocynin attenuate spatial

learning efficis and oxidative responses to intermittent hypoxia. Sleep

Med 2010; 11: 205–12.

32 Nair D, Dayyat EA, Zhang SX, Wang Y, Gozal D. Intermittent hypoxia-

induced cognitive deficits are mediated by NADPH oxidase activity in a

murine model of sleep apnea. PLoS One 2011; 6: e19847.

33 Fung SL, Xi MC, Zhang JH, Sampogna S, Yamuy J, Morales FR, et al.

Apnea promotes glutamate-induced excitotoxicity in hippocampal

neurons. Brain Res 2007; 1179: 42–50.

34 Li RC, Row BW, Kheirandish L, Brittan KR, Gozal E, Guo SZ, et al.

Nitric oxide synthase and intermittent hypoxia-induced spatial learning

deficits in the rat. Neurobiol Dis 2004; 17: 44–53.

35 Ryan S, McNicholos WT, Taylor C. A critical role for p38 map kinase

in NF-kB signaling during intermittent hypoxia/reoxygenation. Biochem

Biophys Res Com 2007; 355: 728–33.

36 Li RC, Row BW, Gozal E, Kheirandish L, Fan Q, Brittan KR, et al.

Cyclooxygenase 2 and intermittent hypoxia-induced spatial deficits in

the rat. Am J Respir Crit Care Med 2003; 15: 469–75.

37 Thoenen H. The changing scene of neurotrophic factors. Trends

Neurosci 1991; 14: 165–70.

38 Lewin GR, Barde YA. Physiology of the neurotrophins. Ann Rev Neuro-

sci 1996; 19: 289–317.

39 Bibel M, Barde YA. Neurotrophins: key regulators of cell fate and

cell shape in the vertebrate nervous system. Genes Dev 2000; 14:

2919–37.

40 Poo MM. Neurotrophin as synaptic modulators Nat. Rev Neurosci

2001; 2: 24–32.

41 Lu B. Acute and long-term synaptic modification by neurotrophins.

Prog Brain Res 2004; 146: 137–50.

42 Rose CR, Blum R, Kafitz KW, Kovalchuk Y, Konnerth A. From

modulator to mediator: rapid effects of BDNF on ion channels. Bio-

essays 2004; 26: 1185–94.

43 Lu Y, Christian K, Lu B. BDNF: a key regulator for protein synthesis-
dependent LTP and long-term memory? Neurobiol Learn Mem 2008;

89: 312–23.

44 Pang P, Teng H, Zaitsev E, Woo NT, Sakata K, Zhen S, et al. Proteolytic

conversion from pro- to mature BDNF by tPA/plasmin is essential for

long-term hippocampal plasticity. Science 2004; 305: 487–91.

45 Egan M, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino

A, et al. The BDNF val66met polymorphism affects activity-dependent

secretion of BDNF and human memory and hippocampal function.

Cell 2003; 112: 527–69.

46 Pezawas L, Verchinski BA, Mattay VS, Callicott JH, Kolachana BS,

Stroab RE, et al. The brain-derived neurotrophic factor val66met poly-

morphism and variation in human cortical morphology. J Neurosci

2004; 24: 10099–102.

47 Chiaretti A, Piastra M, Polidori G, Di Rocco C, Caresta E, Antonell A, et

al. Correlation between neurotrophic factor expression and outcome

of children with severe traumatic brain injury. Intensive Care Med

2003; 29: 1329–38.

48 Chiaretti A, Antonelli A, Piastra M, Genovese O, Polidori G, Aloe L.

Expression of neurotrophic factors in cerebrospinal fluid and plasma

of children with viral and bacterial meningocencephalitis. Acta Paedi-

atr 2004; 93: 1178–84.

49 Dale-Nagle EA, Hoffman MS, MacFarlane PM, Satriotomo I, Lovett-

Barr MR, Vinit S, et al. Spinal plasticity following intermittent hypoxia:

implications for spinal injury. Ann N Y Acad Sci 2010; 1198: 252–9.

50 Vasey SC, Davis CW, Fenik P, Zhan G, Hsu YJ, Pratico D, et al.

Long-term intermittent hypoxia in mice: protracted hypersomnia in

oxidative injury to sleep-wake brain region. Sleep 2004; 27: 194–

201.

51 Polotsky YY, Rubin AE, Balbir A, Dean T, Smith PL, Schwartz AR, et

al. Intermittent hypoxia causes REM sleep deficits and decreases

EEG delta power in NREM sleep in the C57BL/6J mouse. Sleep Med

2006; 7: 7–16.

52 Zhu XY, Yan HC, Zhang J, Qu HD, Qiu XS, Chen L, et al. Intermittent

hypoxia promotes hippocampal neurogenesis and produces anti-

depressant-like effects in adult rats. J Neurosci 2010; 30: 12653–

63.

53 Wilkerson JE, Mitchell GS. Daily intermittent hypoxia augments

spinal BDNF levels, ERK phosphorylation and respiratory long-term

facilitation. Exp Neurol 2009; 217: 116–23.

54 Numakawa T, Matsumoto T, Numakawa Y, Ricahrds M, Yamawaki

S, Kunugi H. Protective action of neurotrophic factors and estrogen

against oxidative stress-mediated neurodegeneration. J Toxicol 2011;

405194.

55 Boutahar N, Reynaud E, Lassabliere F, Borg J. Brain-derived neuro-

trophic factor inhibits cell cycle reentry but not endoplasmic reticulum

stress in cultured neurons following oxidative or excitotoxic stress. J

Neurosci Res 2010; 8: 2263–71.
56 Thomas RJ, Rosen BR, Stern CE, Weiss W, Wong KK. Functional imaging of working memory in obstructive sleep-disordered breathing. J Appl Physiol 2005; 98: 2226–34.

57 Tartar JL, McKenna JT, Ward CP, McCarley RW, Strecker RE, Brown RE. Sleep fragmentation reduces hippocampal CA1 pyramidal cell excitability and response to adenopsine. Neurosci Lett 2010; 469: 1–5.

58 Simmons DA, Rex CS, Palmer L, Pandyanranjan V, Fedulov V, Gall CM, et al. Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington’s disease knockin mice. Proc Natl Acad Sci U S A 2009; 106: 4906–11.

59 Arai AC, Kessler M. Pharmacology of ampakine modulators: from AMPA receptors to synapses and behavior. Curr Drug Targets 2007; 8: 583–602.

60 Nagarajan N, Quast C, Boxall AR, Shahid M, Rosenmund C. Mechanism and impact of allosteric AMPA receptor modulation by the ampakine CX546. Neuropharmacology 2001; 41: 650–63.

61 Kramar EA, Chen LY, Lauterborn JC, Simmons DA, Gall CM, Lynch G. BDNF upregulation rescues synaptic plasticity in middle-aged ovariectomized rats. Neurobiol Aging 2010. doi:10.1016/j.neurobiolaging.2010.06.008

62 Lynch G. Memory enhancement: the search for mechanism-based drugs. Nat Neurosci 2002; 5: 1035–8.

63 Wezenberg E, Verkes RJ, Ruigt GS, Hulstijn W, Sabbe BG. Acute effects of ampakine farampator on memory and information processing in healthy elderly volunteers. Neuropsychopharmacol 2007; 32: 1272–83.